Nothing Special   »   [go: up one dir, main page]

MX2019010802A - Anticuerpos anti-par2 y usos de los mismos. - Google Patents

Anticuerpos anti-par2 y usos de los mismos.

Info

Publication number
MX2019010802A
MX2019010802A MX2019010802A MX2019010802A MX2019010802A MX 2019010802 A MX2019010802 A MX 2019010802A MX 2019010802 A MX2019010802 A MX 2019010802A MX 2019010802 A MX2019010802 A MX 2019010802A MX 2019010802 A MX2019010802 A MX 2019010802A
Authority
MX
Mexico
Prior art keywords
par2
antibodies
antigen
binding fragments
par2 antibodies
Prior art date
Application number
MX2019010802A
Other languages
English (en)
Inventor
Fairman David
Newton Philip
Dobson Claire
Williams Richard
Gurrell Ian
PODICHETTY Sadhana
Thornton Peter
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2019010802A publication Critical patent/MX2019010802A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno capaces de unirse a PAR2. En algunas realizaciones, los anticuerpos anti-PAR2 o fragmentos de unión a antígeno de los mismos se unen a PAR2 de una manera dependiente del pH. La divulgación proporciona además métodos para preparar y usar los anticuerpos y fragmentos de unión a antígeno.
MX2019010802A 2017-03-16 2018-03-16 Anticuerpos anti-par2 y usos de los mismos. MX2019010802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US201862637766P 2018-03-02 2018-03-02
PCT/EP2018/056776 WO2018167322A1 (en) 2017-03-16 2018-03-16 Anti-par2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2019010802A true MX2019010802A (es) 2019-10-30

Family

ID=61827709

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010802A MX2019010802A (es) 2017-03-16 2018-03-16 Anticuerpos anti-par2 y usos de los mismos.

Country Status (20)

Country Link
US (3) US10836822B2 (es)
EP (1) EP3596125A1 (es)
JP (2) JP7222901B2 (es)
KR (1) KR102711884B1 (es)
CN (1) CN110446720B (es)
AU (2) AU2018235031B2 (es)
BR (1) BR112019018752A2 (es)
CA (1) CA3055251A1 (es)
CL (1) CL2019002626A1 (es)
CO (1) CO2019010975A2 (es)
CR (1) CR20190417A (es)
IL (1) IL269134B2 (es)
MA (1) MA49886A (es)
MX (1) MX2019010802A (es)
NZ (1) NZ757915A (es)
PH (1) PH12019502087A1 (es)
SG (1) SG11201908056QA (es)
TW (1) TWI788332B (es)
UA (1) UA125757C2 (es)
WO (1) WO2018167322A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP6032818B2 (ja) 2011-02-25 2016-11-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW202432590A (zh) 2014-12-19 2024-08-16 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
CN114773469A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
CA3192208A1 (en) 2020-08-18 2022-02-24 Cephalon Llc Anti-par-2 antibodies and methods of use thereof
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024156720A1 (en) 2023-01-25 2024-08-02 Medimmune Limited Migraine therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20070053911A1 (en) * 2003-03-11 2007-03-08 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
EP1814911A2 (en) * 2004-11-04 2007-08-08 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
JP2011530515A (ja) * 2008-08-05 2011-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Par−2活性化のエフェクターおよび炎症の調節におけるその使用
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
EP2882778B1 (en) * 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
WO2016000813A1 (en) * 2014-06-30 2016-01-07 Merck Patent Gmbh Anti-tnfa antibodies with ph-dependent antigen binding

Also Published As

Publication number Publication date
UA125757C2 (uk) 2022-06-01
CO2019010975A2 (es) 2019-10-21
AU2021257983A1 (en) 2021-11-25
CR20190417A (es) 2019-12-06
TW201843176A (zh) 2018-12-16
JP2023055895A (ja) 2023-04-18
AU2018235031B2 (en) 2021-08-12
EP3596125A1 (en) 2020-01-22
JP7222901B2 (ja) 2023-02-15
WO2018167322A1 (en) 2018-09-20
US20230242639A1 (en) 2023-08-03
NZ757915A (en) 2023-05-26
KR102711884B1 (ko) 2024-10-02
CN110446720B (zh) 2023-09-12
KR20190129925A (ko) 2019-11-20
US11591389B2 (en) 2023-02-28
PH12019502087A1 (en) 2020-03-09
SG11201908056QA (en) 2019-09-27
AU2018235031A1 (en) 2019-10-31
CN110446720A (zh) 2019-11-12
US20180305450A1 (en) 2018-10-25
IL269134B2 (en) 2024-07-01
JP2020509762A (ja) 2020-04-02
IL269134A (en) 2019-11-28
MA49886A (fr) 2020-06-24
US10836822B2 (en) 2020-11-17
CA3055251A1 (en) 2018-09-20
BR112019018752A2 (pt) 2020-05-05
CL2019002626A1 (es) 2019-12-06
TWI788332B (zh) 2023-01-01
US20210061905A1 (en) 2021-03-04
IL269134B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
MX2024000742A (es) Anticuerpos anti-tigit.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12020551997A1 (en) Psma binding agents and uses thereof
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12018500906A1 (en) Antibodies specifically binding pd-1 and their uses
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12018500482A1 (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
MX2018006583A (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica.
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
PH12019500552A1 (en) Antibody specifically binding to pd-1 and functional fragment thereof
PH12019500551A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
PH12017502207A1 (en) Tau-binding antibodies
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2021008216A (es) Anticuerpos anti-tigit.
EP3527589A4 (en) MONOCLONAL ANTIBODIES BINDING SPECIFICALLY TO THIOREDOXIN 1 AND ITS USE
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.